Introduction: Pharmacometric models represent the most comprehensive approaches for
extracting, summarizing and integrating information obtained in the often sparse, limited …

Certain oncology compounds exhibit fundamental pharmacokinetic (PK) disparities between
healthy and malignant conditions. Given the effects of tumor‐associated inflammation on …

Introduction: Mathematical modeling enables: the in silico classification of cancers, the
prediction of disease outcomes, optimization of therapy, identification of promising drug …

Quantitative systems pharmacology holds the promises of integrating results from laboratory
animals or in vitro human systems into the design of human pharmacokinetic …

An important feature of mechanism-based pharmacokinetic/pharmacodynamic (PK/PD)
models is the identification of drug-and system-specific factors that determine the intensity …

With the advancement of technology, drug delivery systems and molecules with more
complex architecture are developed. As a result, the drug absorption and disposition …

Therapeutic monoclonal antibodies (mAbs) have been a promising therapeutic approach for
several diseases and a wide variety of mAbs are being evaluated in clinical trials. To …

Physiologically based pharmacokinetic (PBPK) modeling and simulation can be used to
predict the pharmacokinetic behavior of drugs in humans using preclinical data. It can also …

Physiologically based pharmacokinetic (PBPK) models are built using differential equations
to describe the physiology/anatomy of different biological systems. Readily available in vitro …

Despite its great promise, personalized oncology still faces many hurdles, and it is
increasingly clear that targeted drugs and molecular biomarkers alone yield only modest …